Don’t Consider Sotagliflozin a Diabetes Med
July 2023
New Rx sotagliflozin (Inpefa) will join dapagliflozin (Farxiga), empagliflozin (Jardiance), and other SGLT2 inhibitors.
But sotagliflozin is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.
It’s currently only approved to reduce the risk of heart failure urgent care visits and hospitalizations and cardiovascular death...in certain adults with OR without diabetes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote